August 2023 in “Frontiers in Oncology” New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.
21 citations
,
May 1989 in “Advanced Drug Delivery Reviews” Liposomes show promise in cancer treatment by delivering drugs with less toxicity and improved effectiveness.
5 citations
,
March 2020 in “Thoracic Cancer” CT-707 is effective and safe for treating certain Chinese lung cancer patients.
March 2015 in “Oncology Times” Extending androgen suppression before radiotherapy offers no extra survival benefit for intermediate-risk prostate cancer.
4 citations
,
January 2016 in “Dermatology Review” Cancer treatments often cause skin, nail, and hair problems.
2 citations
,
January 2025 in “Сибирский научный медицинский журнал” TS-13 effectively stops tumor growth and reduces chemotherapy side effects.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
December 2013 in “Nursing2023” The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
April 2025 in “Journal of Pharma Insights and Research.” Females had more chemotherapy side effects than males, with many being preventable.
March 2025 in “Future Oncology” Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.
January 2005 in “世界胃肠病学杂志:英文版(电子版)” Etoposide makes radiation therapy more effective against tumors without major side effects.
24 citations
,
January 2017 in “International Journal of Trichology” 24 citations
,
February 2016 in “PubMed” Royal jelly can protect the heart from damage caused by paclitaxel.
March 2024 in “Cancer Research” Eliminating senescent cells can prevent and reverse chemotherapy-induced peripheral neuropathy.
Chemotherapy can cause skin issues and hair loss, and this guide explains how to manage them.
January 2023 in “Cutaneous and Ocular Toxicology” June 2026 in “Frontiers in Immunology” Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
39 citations
,
August 2022 in “Pharmaceutics” Combining letrozole and quercetin in spanlastics may improve breast cancer treatment.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
2 citations
,
December 2020 in “JAMA Dermatology” Radiotherapy is a good option when further surgery for skin cancer isn't preferred, but more research is needed to compare it with other methods.
April 2025 in “Journal of Oncology Pharmacy Practice” The scalp lotion helped increase hair thickness in cancer patients undergoing chemotherapy.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
88 citations
,
July 2014 in “Journal of the American Academy of Dermatology” Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
1 citations
,
August 1983 in “PubMed” CVP therapy showed moderate success in treating advanced non-Hodgkin's lymphoma, but more intensive treatment is needed for better outcomes.
45 citations
,
April 2021 in “Current Treatment Options in Oncology” ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.
February 2023 in “Journal of Korean Medical Association” Targeted cancer therapies can cause new side effects, requiring careful monitoring and management to ensure patient safety.
March 2023 in “JAAD case reports” Dutasteride and minoxidil helped regrow hair in a woman with breast cancer.
188 citations
,
October 2014 in “Thyroid” Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.
3 citations
,
July 2019 in “Supportive Care in Cancer” The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.